首頁 > 市場調查報告書 > 製藥

癌症

腫瘤性骨軟化症市場規模、佔有率和成長分析：按診斷、治療、最終用戶和地區分類－2026-2033年產業預測

市場調查報告書

商品編碼

2131517

腫瘤性骨軟化症市場規模、佔有率和成長分析：按診斷、治療、最終用戶和地區分類－2026-2033年產業預測

Tumour-Induced Osteomalacia Market Size, Share, and Growth Analysis, By Diagnosis (Laboratory Testing, Imaging), By Treatment (Surgical Treatment, Drug Therapy), By End User, By Region - Industry Forecast 2026-2033

出版日期: 2026年08月26日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2024 年全球腫瘤誘發骨軟化症市場價值為 1.74 億美元，預計到 2033 年將從 2025 年的 1.9575 億美元成長至 5.0226 億美元，預測期（2026-2033 年）複合年成長率為 12.5%。

全球腫瘤性骨軟化症 (TIO) 市場以診斷試劑盒和外科療法的創新與商業化為特徵，同時湧現出一類新型藥物，例如纖維母細胞生長因子-23 (FGF-23) 抗體（如布羅索單抗）。儘管 TIO 是一種罕見疾病，但其對骨鈣化的嚴重影響催生了對標靶治療的強勁需求。最初，由於認知度低和侵入性治療的存在，該市場面臨挑戰，但近期的技術進步和孤兒藥監管支持推動了市場成長。人工智慧成像技術的應用提高了診斷準確性，實現了腫瘤的早期識別，從而為早期治療鋪平了道路。這些技術的整合不僅改善了手術效果，也加速了療法的推廣應用，吸引了大量投資湧入 TIO 領域的生技創新。

全球腫瘤誘發骨軟化症市場的成長要素

由於臨床醫師對腫瘤性骨軟化症的細微徵兆認知不斷提高，全球市場需求日益成長。這種認知的提高促使患者更早轉診，並進行更詳細的診斷評估。因此，先進影像技術的應用不斷推進，內分泌科醫生、腫瘤科醫生和放射科醫生等專科醫生之間的合作也日益加強。這些進步簡化了患者照護流程，最大限度地減少了診斷延誤，並提高了治療方案的可近性。此外，教育活動和最新的臨床指南在強調早期檢測的重要性方面發揮著至關重要的作用，這反過來又推動了市場對相關醫療產品和服務的持續需求。

全球腫瘤誘發骨軟化症市場的限制因素

腫瘤性骨軟化症的全球市場發展受到嚴重限制，尤其是在資源匱乏地區，精準診斷所需的專業影像技術普及程度參差不齊。這種差距導致病灶識別延遲、患者不適感延長，以及必要的治療性介入被推遲。缺乏足夠影像設備的醫療機構往往被迫使用效果較差的替代方案，這可能導致診斷結果不明確，並增加臨床不確定性。因此，市場上先進診斷工具的普及受到限制，最終阻礙了相關療法在全球醫療系統中的廣泛應用。

全球腫瘤誘發性骨軟化症市場趨勢

腫瘤誘發骨軟化症的全球市場正經歷顯著的變革，這主要得益於精準基因體學在診斷和治療策略中的應用。次世代定序和標靶基因檢測技術的進步，使臨床醫生能夠準確識別潛在的間葉腫瘤，從而促進早期診斷和個人化治療性介入。這種對基因組學的關注，推動了腫瘤學、內分泌學和分子病理學之間的跨學科合作，最終促成了高效、多學科臨床部門的建立，進而改善了患者照護。此外，隨著我們對遺傳因素理解的不斷深入，製藥公司正致力於開發伴隨診斷，從而催生大量個人化最佳化療法，推動著全球不同醫療機構的市場格局不斷變化。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太國家
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲國家

競爭資訊

前五大公司對比
主要公司2025年的市場定位
主要市場公司採取的策略
近期市場趨勢
企業市場占有率分析，2025 年
主要公司的完整公司簡介
- 公司詳情
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 銷售收入年比比較（2023-2025 年）

主要公司簡介

Kyowa Kirin Co., Ltd.
Ultragenyx Pharmaceutical Inc.
Inozyme Pharma, Inc.
BridgeBio Pharma, Inc.
Ascendis Pharma A/S
Amgen Inc.
Novartis AG
Regeneron Pharmaceuticals, Inc.
AstraZeneca PLC
Pfizer Inc.
Sanofi SA
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Eli Lilly and Company
AbbVie Inc.
Takeda Pharmaceutical Company Limited
Novo Nordisk A/S
Ipsen SA
BioMarin Pharmaceutical Inc.
Alexion Pharmaceuticals, Inc.

結論與建議

簡介目錄

Product Code: SQMIG35I3588

Global Tumour-Induced Osteomalacia Market size was valued at USD 174.0 Million in 2024 and is poised to grow from USD 195.75 Million in 2025 to USD 502.26 Million by 2033, growing at a CAGR of 12.5% during the forecast period (2026-2033).

The global market for tumour-induced osteomalacia (TIO) is characterized by the innovation and commercialization of diagnostic kits, surgical options, and the novel class of fibroblast growth factor-23 (FGF-23) antibodies such as burosumab. The rarity of TIO, combined with its serious effects on bone mineralization, creates a robust demand for targeted therapies. Though the market initially faced challenges due to limited awareness and invasive treatment options, recent advancements and regulatory support for orphan drugs have fostered growth. The utilization of AI-driven imaging technologies enhances diagnostic accuracy and facilitates timely tumor localization, promoting earlier treatment pathways. This integration not only improves surgical outcomes but also drives an increase in treatment adoption, attracting significant investment in biotech innovations within the TIO space.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Tumour-Induced Osteomalacia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Tumour-Induced Osteomalacia Market Segments Analysis

Global tumour-induced osteomalacia market is segmented by diagnosis, treatment, end user and region. Based on diagnosis, the market is segmented into Laboratory Testing, Imaging and Tumor Localization Techniques. Based on treatment, the market is segmented into Surgical Treatment, Drug Therapy and Supportive Care. Based on end user, the market is segmented into Hospitals, Specialty Clinics, Diagnostic Centers and Academic & Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Tumour-Induced Osteomalacia Market

The Global Tumour-Induced Osteomalacia market is experiencing growth driven by improved clinician awareness regarding the subtle indicators of the condition. This increased recognition leads to earlier patient referrals and more extensive diagnostic evaluations. Consequently, there is a rising adoption of advanced imaging technologies and enhanced collaboration among specialists such as endocrinologists, oncologists, and radiologists. These advancements streamline patient care pathways, minimizing diagnostic delays and promoting the availability of therapeutic solutions. Moreover, educational initiatives and updated clinical guidelines play a crucial role in emphasizing the significance of early detection, thus fueling ongoing demand for related medical products and services within the market.

Restraints in the Global Tumour-Induced Osteomalacia Market

The global Tumour-Induced Osteomalacia market is significantly hindered by inconsistent access to specialized imaging technologies essential for accurate diagnosis, particularly in under-resourced areas. This disparity results in delays in identifying the underlying lesions, prolonging patient discomfort and postponing necessary treatment interventions. Healthcare facilities without the appropriate imaging capabilities are often forced to use less effective alternatives, which may yield ambiguous results and exacerbate clinical uncertainty. As a result, there is a limited adoption of advanced diagnostic tools in the market, ultimately impeding the broader acceptance and implementation of related treatment options within the healthcare system worldwide.

Market Trends of the Global Tumour-Induced Osteomalacia Market

The Global Tumour-Induced Osteomalacia market is experiencing a significant evolution driven by the integration of precision genomics in diagnostics and treatment strategies. The shift towards next-generation sequencing and targeted gene panels empowers clinicians to accurately identify underlying mesenchymal tumors, facilitating early diagnosis and personalized therapeutic interventions. This genomic emphasis fosters interdisciplinary collaboration among oncology, endocrinology, and molecular pathology, leading to the establishment of streamlined, multidisciplinary clinics that enhance patient care. Furthermore, as the understanding of genetic factors increases, pharmaceutical companies are focusing on developing companion diagnostics, resulting in a surge of tailored therapies that are propelling market growth across diverse global healthcare landscapes.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index 2025
PESTEL Analysis
Regulatory Landscape

Global Tumour-Induced Osteomalacia Market Size by Diagnosis & CAGR (2026-2033)

Market Overview
Laboratory Testing
Imaging
Tumor Localization Techniques

Global Tumour-Induced Osteomalacia Market Size by Treatment & CAGR (2026-2033)

Market Overview
Surgical Treatment
Drug Therapy
- FGF23 Inhibitors
- Phosphate & Vitamin D Therapy
Supportive Care

Global Tumour-Induced Osteomalacia Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals
Specialty Clinics
Diagnostic Centers
Academic & Research Institutes

Global Tumour-Induced Osteomalacia Market Size & CAGR (2026-2033)

North America (Diagnosis, Treatment, End User)
- US
- Canada
Europe (Diagnosis, Treatment, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Diagnosis, Treatment, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Diagnosis, Treatment, End User)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Diagnosis, Treatment, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Kyowa Kirin Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ultragenyx Pharmaceutical Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Inozyme Pharma, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BridgeBio Pharma, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ascendis Pharma A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novo Nordisk A/S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ipsen S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioMarin Pharmaceutical Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alexion Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments